Preload Image
Preload Image
Report Store mobile icon
Global Systemic Anti-infective Drugs Market Growth 2024-2030

Global Systemic Anti-infective Drugs Market Growth 2024-2030

2024

Global Systemic Anti-infective Drugs Market Growth 2024-2030

The Systemic Anti-infective Drugs market is projected to grow from US$ 16,140 million in 2024 to US$ 20,000 million in 2030, driven by demand for effective treatments.

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global systemic anti-infective drugs market has witnessed substantial growth over recent years, driven by the rising prevalence of infectious diseases, the continuous emergence of new pathogens, and advancements in pharmaceutical research. Systemic anti-infective drugs are used to treat infections that affect the entire body, including bacterial, viral, fungal, and parasitic infections. These drugs play a crucial role in the management and treatment of various life-threatening conditions, including sepsis, pneumonia, and HIV/AIDS, among others. As the global population continues to grow, particularly in emerging economies, the demand for effective anti-infective drugs is escalating. The aging population is also a key factor contributing to the market’s expansion, as older individuals are more susceptible to infections due to weakened immune systems. The rise in healthcare spending, coupled with improvements in healthcare infrastructure, has allowed for broader access to treatment options, contributing to the market’s growth. The increasing incidence of antibiotic resistance, however, presents both challenges and opportunities for the systemic anti-infective drugs market. The growing resistance to conventional antibiotics has driven the need for the development of new, more potent drugs. Additionally, the global rise of hospital-acquired infections (HAIs) and the increasing number of immunocompromised patients, such as those undergoing chemotherapy or organ transplantation, are further boosting the demand for systemic anti-infective treatments. With ongoing advancements in drug formulations, the development of novel drug classes, and increasing research into combination therapies, the systemic anti-infective drugs market is poised for continued growth in the coming years.

According to Publisher, the global Systemic Anti-infective Drugs market size is projected to grow from US$ 16140 million in 2024 to US$ 20000 million in 2030; it is expected to grow at a CAGR of 3.1% from 2024 to 2030. The rise in drug-resistant infections has emerged as a key driver of innovation in the systemic anti-infective drugs market. In recent years, there has been a growing focus on the development of next-generation antibiotics and antiviral drugs that can combat resistant strains of bacteria and viruses. The market is witnessing a shift toward the development of more targeted therapies, as researchers and pharmaceutical companies work to create drugs that specifically target pathogens while minimizing side effects. One example of this is the development of broad-spectrum antibiotics and antiviral agents that are effective against a wide range of pathogens, offering hope for more comprehensive treatment options in the fight against infectious diseases. Additionally, the increasing popularity of combination therapies, which involve the use of multiple drugs in conjunction to enhance efficacy and reduce resistance, has contributed to the market’s expansion. The use of such treatments helps improve patient outcomes by addressing multiple types of infections simultaneously, reducing the risk of drug resistance. Another important factor influencing market growth is the ongoing rise in the prevalence of chronic infectious diseases, such as HIV, tuberculosis, and hepatitis, which require long-term anti-infective therapy. In addition, the increasing use of anti-infective drugs in the prevention of infections during surgical procedures and in high-risk patients has added to the demand for these drugs. The COVID-19 pandemic has also highlighted the urgent need for effective antiviral and anti-infective therapies, driving innovation and increasing investments in the development of drugs to combat new and emerging pathogens. These factors, combined with increased government support for research and the development of novel anti-infective agents, are expected to further propel the growth of the systemic anti-infective drugs market.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The systemic anti-infective drugs market can be segmented by drug class, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are the largest and most well-established segment in the market, with a broad range of drugs available to treat bacterial infections. Within the antibiotics category, beta-lactams, macrolides, tetracyclines, and quinolones are among the most commonly used classes of antibiotics. However, the growing concern over antibiotic resistance has led to the development of new classes of antibiotics, such as oxazolidinones and glycylcyclines, which are designed to treat infections caused by multi-drug resistant bacteria. Antivirals represent the second-largest segment in the systemic anti-infective drugs market, driven by the increasing prevalence of viral infections, such as HIV, influenza, and hepatitis. The development of antiretroviral drugs for the treatment of HIV/AIDS has been a key driver of this segment, with significant advancements in combination therapies that help to manage the disease. Additionally, the ongoing research into antiviral drugs for emerging viral infections, such as COVID-19, is contributing to the growth of this segment. Antifungals are used to treat fungal infections, which can affect various parts of the body, including the skin, lungs, and central nervous system. The antifungal drug market is expanding due to the increasing incidence of fungal infections, particularly in immunocompromised patients. Lastly, antiparasitic drugs are used to treat infections caused by parasites, such as malaria and helminthic infections. The increasing prevalence of parasitic infections in tropical and subtropical regions, along with the rise in international travel, is boosting the demand for antiparasitic treatments. The segmentation of the systemic anti-infective drugs market by drug class highlights the diversity of therapeutic options available for treating different types of infections and the ongoing efforts to develop new and more effective treatments to combat emerging infectious threats.

The systemic anti-infective drugs market is also segmented by application, which includes hospitals, clinics, and home care settings. Hospitals represent the largest end-user segment, as they are the primary healthcare setting for the treatment of severe infections and the management of complex cases, including sepsis and multi-drug resistant infections. Hospital patients often require intensive treatment with systemic anti-infective drugs, such as intravenous antibiotics or antiviral agents, to manage infections that are difficult to treat or life-threatening. Additionally, hospitals serve as the primary site for surgeries and procedures that may require prophylactic anti-infective treatment to prevent infections. The rising number of hospital-acquired infections (HAIs) has further increased the demand for anti-infective drugs in these settings. Clinics represent another important end-user segment, as they are increasingly used for the diagnosis and treatment of infections, particularly less severe conditions that can be managed with oral medications. In clinics, patients often receive outpatient care for common infections, such as respiratory or urinary tract infections, and may be prescribed systemic antibiotics or antivirals. The increasing availability of rapid diagnostic tools and point-of-care testing in clinics has also contributed to the growth of this segment. Home care settings are becoming a significant application area, as more patients with chronic infections or those undergoing long-term treatment for conditions such as HIV or tuberculosis are being managed in home care environments. Advances in telemedicine and remote monitoring technologies have made it easier for healthcare providers to manage patients at home, reducing the need for hospitalization and improving patient comfort. The segmentation by application reflects the growing importance of systemic anti-infective drugs across various healthcare settings, with hospitals continuing to be the primary end-user segment while clinics and home care settings are playing an increasingly vital role in infection management.


Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Systemic Anti-infective Drugs Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Systemic Anti-infective Drugs by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Systemic Anti-infective Drugs by Country/Region, 2019, 2023 & 2030
  • 2.2 Systemic Anti-infective Drugs Segment by Type
  • 2.2.1 Antibacterial Drugs
  • 2.2.2 Antifungals
  • 2.2.3 Antiviral and Antiparasitic Drugs
  • 2.3 Systemic Anti-infective Drugs Sales by Type
  • 2.3.1 Global Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Systemic Anti-infective Drugs Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Systemic Anti-infective Drugs Sale Price by Type (2019-2024)
  • 2.4 Systemic Anti-infective Drugs Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Clinic
  • 2.4.3 Other
  • 2.5 Systemic Anti-infective Drugs Sales by Application
  • 2.5.1 Global Systemic Anti-infective Drugs Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Systemic Anti-infective Drugs Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Systemic Anti-infective Drugs Sale Price by Application (2019-2024)
  • 3 Global Systemic Anti-infective Drugs by Company
  • 3.1 Global Systemic Anti-infective Drugs Breakdown Data by Company
  • 3.1.1 Global Systemic Anti-infective Drugs Annual Sales by Company (2019-2024)
  • 3.1.2 Global Systemic Anti-infective Drugs Sales Market Share by Company (2019-2024)
  • 3.2 Global Systemic Anti-infective Drugs Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Systemic Anti-infective Drugs Revenue by Company (2019-2024)
  • 3.2.2 Global Systemic Anti-infective Drugs Revenue Market Share by Company (2019-2024)
  • 3.3 Global Systemic Anti-infective Drugs Sale Price by Company
  • 3.4 Key Manufacturers Systemic Anti-infective Drugs Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Systemic Anti-infective Drugs Product Location Distribution
  • 3.4.2 Players Systemic Anti-infective Drugs Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Systemic Anti-infective Drugs by Geographic Region
  • 4.1 World Historic Systemic Anti-infective Drugs Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Systemic Anti-infective Drugs Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Systemic Anti-infective Drugs Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Systemic Anti-infective Drugs Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Systemic Anti-infective Drugs Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Systemic Anti-infective Drugs Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Systemic Anti-infective Drugs Sales Growth
  • 4.4 APAC Systemic Anti-infective Drugs Sales Growth
  • 4.5 Europe Systemic Anti-infective Drugs Sales Growth
  • 4.6 Middle East & Africa Systemic Anti-infective Drugs Sales Growth
  • 5 Americas
  • 5.1 Americas Systemic Anti-infective Drugs Sales by Country
  • 5.1.1 Americas Systemic Anti-infective Drugs Sales by Country (2019-2024)
  • 5.1.2 Americas Systemic Anti-infective Drugs Revenue by Country (2019-2024)
  • 5.2 Americas Systemic Anti-infective Drugs Sales by Type
  • 5.3 Americas Systemic Anti-infective Drugs Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Systemic Anti-infective Drugs Sales by Region
  • 6.1.1 APAC Systemic Anti-infective Drugs Sales by Region (2019-2024)
  • 6.1.2 APAC Systemic Anti-infective Drugs Revenue by Region (2019-2024)
  • 6.2 APAC Systemic Anti-infective Drugs Sales by Type
  • 6.3 APAC Systemic Anti-infective Drugs Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Systemic Anti-infective Drugs by Country
  • 7.1.1 Europe Systemic Anti-infective Drugs Sales by Country (2019-2024)
  • 7.1.2 Europe Systemic Anti-infective Drugs Revenue by Country (2019-2024)
  • 7.2 Europe Systemic Anti-infective Drugs Sales by Type
  • 7.3 Europe Systemic Anti-infective Drugs Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Systemic Anti-infective Drugs by Country
  • 8.1.1 Middle East & Africa Systemic Anti-infective Drugs Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Systemic Anti-infective Drugs Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Systemic Anti-infective Drugs Sales by Type
  • 8.3 Middle East & Africa Systemic Anti-infective Drugs Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Systemic Anti-infective Drugs
  • 10.3 Manufacturing Process Analysis of Systemic Anti-infective Drugs
  • 10.4 Industry Chain Structure of Systemic Anti-infective Drugs
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Systemic Anti-infective Drugs Distributors
  • 11.3 Systemic Anti-infective Drugs Customer
  • 12 World Forecast Review for Systemic Anti-infective Drugs by Geographic Region
  • 12.1 Global Systemic Anti-infective Drugs Market Size Forecast by Region
  • 12.1.1 Global Systemic Anti-infective Drugs Forecast by Region (2025-2030)
  • 12.1.2 Global Systemic Anti-infective Drugs Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Systemic Anti-infective Drugs Forecast by Type
  • 12.7 Global Systemic Anti-infective Drugs Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Pfizer
  • 13.1.1 Pfizer Company Information
  • 13.1.2 Pfizer Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.1.3 Pfizer Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Pfizer Main Business Overview
  • 13.1.5 Pfizer Latest Developments
  • 13.2 Sumitomo Dainippon Pharma
  • 13.2.1 Sumitomo Dainippon Pharma Company Information
  • 13.2.2 Sumitomo Dainippon Pharma Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.2.3 Sumitomo Dainippon Pharma Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 Sumitomo Dainippon Pharma Main Business Overview
  • 13.2.5 Sumitomo Dainippon Pharma Latest Developments
  • 13.3 MSD
  • 13.3.1 MSD Company Information
  • 13.3.2 MSD Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.3.3 MSD Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 MSD Main Business Overview
  • 13.3.5 MSD Latest Developments
  • 13.4 Bayer
  • 13.4.1 Bayer Company Information
  • 13.4.2 Bayer Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.4.3 Bayer Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Bayer Main Business Overview
  • 13.4.5 Bayer Latest Developments
  • 13.5 Bristol-Myers Squibb
  • 13.5.1 Bristol-Myers Squibb Company Information
  • 13.5.2 Bristol-Myers Squibb Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.5.3 Bristol-Myers Squibb Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 Bristol-Myers Squibb Main Business Overview
  • 13.5.5 Bristol-Myers Squibb Latest Developments
  • 13.6 Dechra
  • 13.6.1 Dechra Company Information
  • 13.6.2 Dechra Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.6.3 Dechra Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Dechra Main Business Overview
  • 13.6.5 Dechra Latest Developments
  • 13.7 Alandalous
  • 13.7.1 Alandalous Company Information
  • 13.7.2 Alandalous Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.7.3 Alandalous Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Alandalous Main Business Overview
  • 13.7.5 Alandalous Latest Developments
  • 13.8 Zhengda Tianqing
  • 13.8.1 Zhengda Tianqing Company Information
  • 13.8.2 Zhengda Tianqing Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.8.3 Zhengda Tianqing Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Zhengda Tianqing Main Business Overview
  • 13.8.5 Zhengda Tianqing Latest Developments
  • 13.9 Luoxin Pharmaceutical
  • 13.9.1 Luoxin Pharmaceutical Company Information
  • 13.9.2 Luoxin Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.9.3 Luoxin Pharmaceutical Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 Luoxin Pharmaceutical Main Business Overview
  • 13.9.5 Luoxin Pharmaceutical Latest Developments
  • 13.10 Southwest Pharmaceutical
  • 13.10.1 Southwest Pharmaceutical Company Information
  • 13.10.2 Southwest Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.10.3 Southwest Pharmaceutical Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.10.4 Southwest Pharmaceutical Main Business Overview
  • 13.10.5 Southwest Pharmaceutical Latest Developments
  • 13.11 Guangzhou Baiyun Mountain
  • 13.11.1 Guangzhou Baiyun Mountain Company Information
  • 13.11.2 Guangzhou Baiyun Mountain Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.11.3 Guangzhou Baiyun Mountain Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.11.4 Guangzhou Baiyun Mountain Main Business Overview
  • 13.11.5 Guangzhou Baiyun Mountain Latest Developments
  • 13.12 Harbin Pharmaceutical Group
  • 13.12.1 Harbin Pharmaceutical Group Company Information
  • 13.12.2 Harbin Pharmaceutical Group Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.12.3 Harbin Pharmaceutical Group Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.12.4 Harbin Pharmaceutical Group Main Business Overview
  • 13.12.5 Harbin Pharmaceutical Group Latest Developments
  • 13.13 CSPC
  • 13.13.1 CSPC Company Information
  • 13.13.2 CSPC Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.13.3 CSPC Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.13.4 CSPC Main Business Overview
  • 13.13.5 CSPC Latest Developments
  • 13.14 North China Pharmaceutical
  • 13.14.1 North China Pharmaceutical Company Information
  • 13.14.2 North China Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.14.3 North China Pharmaceutical Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.14.4 North China Pharmaceutical Main Business Overview
  • 13.14.5 North China Pharmaceutical Latest Developments
  • 13.15 Sinopharm Group
  • 13.15.1 Sinopharm Group Company Information
  • 13.15.2 Sinopharm Group Systemic Anti-infective Drugs Product Portfolios and Specifications
  • 13.15.3 Sinopharm Group Systemic Anti-infective Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.15.4 Sinopharm Group Main Business Overview
  • 13.15.5 Sinopharm Group Latest Developments
  • 14 Research Findings and Conclusion


Table 1. Systemic Anti-infective Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Systemic Anti-infective Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Antibacterial Drugs
Table 4. Major Players of Antifungals
Table 5. Major Players of Antiviral and Antiparasitic Drugs
Table 6. Global Systemic Anti-infective Drugs Sales by Type (2019-2024) & (K Units)
Table 7. Global Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
Table 8. Global Systemic Anti-infective Drugs Revenue by Type (2019-2024) & ($ million)
Table 9. Global Systemic Anti-infective Drugs Revenue Market Share by Type (2019-2024)
Table 10. Global Systemic Anti-infective Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 11. Global Systemic Anti-infective Drugs Sales by Application (2019-2024) & (K Units)
Table 12. Global Systemic Anti-infective Drugs Sales Market Share by Application (2019-2024)
Table 13. Global Systemic Anti-infective Drugs Revenue by Application (2019-2024)
Table 14. Global Systemic Anti-infective Drugs Revenue Market Share by Application (2019-2024)
Table 15. Global Systemic Anti-infective Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 16. Global Systemic Anti-infective Drugs Sales by Company (2019-2024) & (K Units)
Table 17. Global Systemic Anti-infective Drugs Sales Market Share by Company (2019-2024)
Table 18. Global Systemic Anti-infective Drugs Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Systemic Anti-infective Drugs Revenue Market Share by Company (2019-2024)
Table 20. Global Systemic Anti-infective Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 21. Key Manufacturers Systemic Anti-infective Drugs Producing Area Distribution and Sales Area
Table 22. Players Systemic Anti-infective Drugs Products Offered
Table 23. Systemic Anti-infective Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Systemic Anti-infective Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Systemic Anti-infective Drugs Sales Market Share Geographic Region (2019-2024)
Table 28. Global Systemic Anti-infective Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Systemic Anti-infective Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Systemic Anti-infective Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Systemic Anti-infective Drugs Sales Market Share by Country/Region (2019-2024)
Table 32. Global Systemic Anti-infective Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Systemic Anti-infective Drugs Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Systemic Anti-infective Drugs Sales by Country (2019-2024) & (K Units)
Table 35. Americas Systemic Anti-infective Drugs Sales Market Share by Country (2019-2024)
Table 36. Americas Systemic Anti-infective Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Systemic Anti-infective Drugs Revenue Market Share by Country (2019-2024)
Table 38. Americas Systemic Anti-infective Drugs Sales by Type (2019-2024) & (K Units)
Table 39. Americas Systemic Anti-infective Drugs Sales by Application (2019-2024) & (K Units)
Table 40. APAC Systemic Anti-infective Drugs Sales by Region (2019-2024) & (K Units)
Table 41. APAC Systemic Anti-infective Drugs Sales Market Share by Region (2019-2024)
Table 42. APAC Systemic Anti-infective Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Systemic Anti-infective Drugs Revenue Market Share by Region (2019-2024)
Table 44. APAC Systemic Anti-infective Drugs Sales by Type (2019-2024) & (K Units)
Table 45. APAC Systemic Anti-infective Drugs Sales by Application (2019-2024) & (K Units)
Table 46. Europe Systemic Anti-infective Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Europe Systemic Anti-infective Drugs Sales Market Share by Country (2019-2024)
Table 48. Europe Systemic Anti-infective Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Systemic Anti-infective Drugs Revenue Market Share by Country (2019-2024)
Table 50. Europe Systemic Anti-infective Drugs Sales by Type (2019-2024) & (K Units)
Table 51. Europe Systemic Anti-infective Drugs Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Systemic Anti-infective Drugs Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Systemic Anti-infective Drugs Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Systemic Anti-infective Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Systemic Anti-infective Drugs Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Systemic Anti-infective Drugs Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Systemic Anti-infective Drugs Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Systemic Anti-infective Drugs
Table 59. Key Market Challenges & Risks of Systemic Anti-infective Drugs
Table 60. Key Industry Trends of Systemic Anti-infective Drugs
Table 61. Systemic Anti-infective Drugs Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Systemic Anti-infective Drugs Distributors List
Table 64. Systemic Anti-infective Drugs Customer List
Table 65. Global Systemic Anti-infective Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Systemic Anti-infective Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Systemic Anti-infective Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Systemic Anti-infective Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Systemic Anti-infective Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Systemic Anti-infective Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Systemic Anti-infective Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Systemic Anti-infective Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Systemic Anti-infective Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Systemic Anti-infective Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Systemic Anti-infective Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Systemic Anti-infective Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Systemic Anti-infective Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Systemic Anti-infective Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Pfizer Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 81. Pfizer Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Sumitomo Dainippon Pharma Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Sumitomo Dainippon Pharma Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 86. Sumitomo Dainippon Pharma Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. Sumitomo Dainippon Pharma Main Business
Table 88. Sumitomo Dainippon Pharma Latest Developments
Table 89. MSD Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. MSD Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 91. MSD Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. MSD Main Business
Table 93. MSD Latest Developments
Table 94. Bayer Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 96. Bayer Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. Bayer Main Business
Table 98. Bayer Latest Developments
Table 99. Bristol-Myers Squibb Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Bristol-Myers Squibb Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 101. Bristol-Myers Squibb Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Bristol-Myers Squibb Main Business
Table 103. Bristol-Myers Squibb Latest Developments
Table 104. Dechra Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Dechra Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 106. Dechra Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Dechra Main Business
Table 108. Dechra Latest Developments
Table 109. Alandalous Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Alandalous Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 111. Alandalous Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Alandalous Main Business
Table 113. Alandalous Latest Developments
Table 114. Zhengda Tianqing Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Zhengda Tianqing Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 116. Zhengda Tianqing Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. Zhengda Tianqing Main Business
Table 118. Zhengda Tianqing Latest Developments
Table 119. Luoxin Pharmaceutical Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Luoxin Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 121. Luoxin Pharmaceutical Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. Luoxin Pharmaceutical Main Business
Table 123. Luoxin Pharmaceutical Latest Developments
Table 124. Southwest Pharmaceutical Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Southwest Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 126. Southwest Pharmaceutical Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Southwest Pharmaceutical Main Business
Table 128. Southwest Pharmaceutical Latest Developments
Table 129. Guangzhou Baiyun Mountain Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Guangzhou Baiyun Mountain Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 131. Guangzhou Baiyun Mountain Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Guangzhou Baiyun Mountain Main Business
Table 133. Guangzhou Baiyun Mountain Latest Developments
Table 134. Harbin Pharmaceutical Group Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Harbin Pharmaceutical Group Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 136. Harbin Pharmaceutical Group Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. Harbin Pharmaceutical Group Main Business
Table 138. Harbin Pharmaceutical Group Latest Developments
Table 139. CSPC Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. CSPC Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 141. CSPC Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. CSPC Main Business
Table 143. CSPC Latest Developments
Table 144. North China Pharmaceutical Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. North China Pharmaceutical Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 146. North China Pharmaceutical Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. North China Pharmaceutical Main Business
Table 148. North China Pharmaceutical Latest Developments
Table 149. Sinopharm Group Basic Information, Systemic Anti-infective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. Sinopharm Group Systemic Anti-infective Drugs Product Portfolios and Specifications
Table 151. Sinopharm Group Systemic Anti-infective Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Sinopharm Group Main Business
Table 153. Sinopharm Group Latest Developments
List of


Figure 1. Picture of Systemic Anti-infective Drugs
Figure 2. Systemic Anti-infective Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Systemic Anti-infective Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Systemic Anti-infective Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Systemic Anti-infective Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Antibacterial Drugs
Figure 10. Product Picture of Antifungals
Figure 11. Product Picture of Antiviral and Antiparasitic Drugs
Figure 12. Global Systemic Anti-infective Drugs Sales Market Share by Type in 2023
Figure 13. Global Systemic Anti-infective Drugs Revenue Market Share by Type (2019-2024)
Figure 14. Systemic Anti-infective Drugs Consumed in Hospital
Figure 15. Global Systemic Anti-infective Drugs Market: Hospital (2019-2024) & (K Units)
Figure 16. Systemic Anti-infective Drugs Consumed in Clinic
Figure 17. Global Systemic Anti-infective Drugs Market: Clinic (2019-2024) & (K Units)
Figure 18. Systemic Anti-infective Drugs Consumed in Other
Figure 19. Global Systemic Anti-infective Drugs Market: Other (2019-2024) & (K Units)
Figure 20. Global Systemic Anti-infective Drugs Sales Market Share by Application (2023)
Figure 21. Global Systemic Anti-infective Drugs Revenue Market Share by Application in 2023
Figure 22. Systemic Anti-infective Drugs Sales Market by Company in 2023 (K Units)
Figure 23. Global Systemic Anti-infective Drugs Sales Market Share by Company in 2023
Figure 24. Systemic Anti-infective Drugs Revenue Market by Company in 2023 ($ Million)
Figure 25. Global Systemic Anti-infective Drugs Revenue Market Share by Company in 2023
Figure 26. Global Systemic Anti-infective Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 27. Global Systemic Anti-infective Drugs Revenue Market Share by Geographic Region in 2023
Figure 28. Americas Systemic Anti-infective Drugs Sales 2019-2024 (K Units)
Figure 29. Americas Systemic Anti-infective Drugs Revenue 2019-2024 ($ Millions)
Figure 30. APAC Systemic Anti-infective Drugs Sales 2019-2024 (K Units)
Figure 31. APAC Systemic Anti-infective Drugs Revenue 2019-2024 ($ Millions)
Figure 32. Europe Systemic Anti-infective Drugs Sales 2019-2024 (K Units)
Figure 33. Europe Systemic Anti-infective Drugs Revenue 2019-2024 ($ Millions)
Figure 34. Middle East & Africa Systemic Anti-infective Drugs Sales 2019-2024 (K Units)
Figure 35. Middle East & Africa Systemic Anti-infective Drugs Revenue 2019-2024 ($ Millions)
Figure 36. Americas Systemic Anti-infective Drugs Sales Market Share by Country in 2023
Figure 37. Americas Systemic Anti-infective Drugs Revenue Market Share by Country in 2023
Figure 38. Americas Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
Figure 39. Americas Systemic Anti-infective Drugs Sales Market Share by Application (2019-2024)
Figure 40. United States Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 41. Canada Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 42. Mexico Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 43. Brazil Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 44. APAC Systemic Anti-infective Drugs Sales Market Share by Region in 2023
Figure 45. APAC Systemic Anti-infective Drugs Revenue Market Share by Regions in 2023
Figure 46. APAC Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
Figure 47. APAC Systemic Anti-infective Drugs Sales Market Share by Application (2019-2024)
Figure 48. China Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 49. Japan Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. South Korea Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. Southeast Asia Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. India Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. Australia Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. China Taiwan Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. Europe Systemic Anti-infective Drugs Sales Market Share by Country in 2023
Figure 56. Europe Systemic Anti-infective Drugs Revenue Market Share by Country in 2023
Figure 57. Europe Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
Figure 58. Europe Systemic Anti-infective Drugs Sales Market Share by Application (2019-2024)
Figure 59. Germany Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 60. France Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. UK Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. Italy Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 63. Russia Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. Middle East & Africa Systemic Anti-infective Drugs Sales Market Share by Country in 2023
Figure 65. Middle East & Africa Systemic Anti-infective Drugs Revenue Market Share by Country in 2023
Figure 66. Middle East & Africa Systemic Anti-infective Drugs Sales Market Share by Type (2019-2024)
Figure 67. Middle East & Africa Systemic Anti-infective Drugs Sales Market Share by Application (2019-2024)
Figure 68. Egypt Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 69. South Africa Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. Israel Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Turkey Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 72. GCC Country Systemic Anti-infective Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Systemic Anti-infective Drugs in 2023
Figure 74. Manufacturing Process Analysis of Systemic Anti-infective Drugs
Figure 75. Industry Chain Structure of Systemic Anti-infective Drugs
Figure 76. Channels of Distribution
Figure 77. Global Systemic Anti-infective Drugs Sales Market Forecast by Region (2025-2030)
Figure 78. Global Systemic Anti-infective Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 79. Global Systemic Anti-infective Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 80. Global Systemic Anti-infective Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 81. Global Systemic Anti-infective Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 82. Global Systemic Anti-infective Drugs Revenue Market Share Forecast by Application (2025-2030)

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (25 May, 2026)
  • Notify To Team (25 May, 2026)
  • Report updation (26 May, 2026)
  • Report Quality Check (26 May, 2026)
  • Report Dispatch (27 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Systemic Anti-infective Drugs Market Growth 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.